Palantir has continued its expansion into the healthcare and biotechnology sector, by joining forces with Dewpoint Therapeutics.

Let’s take a look at a couple companies that recently took another step in their growth stories.

We’ve heard the warnings for months now: a substantial bearish correction will hit the markets soon.

“History does not repeat itself, but it often rhymes”, is a famous quote from American author Mark Twain and perfectly encapsulates the recent repeat of the Reddit short squeeze from January.

Watch how the stock reacts to earnings and if it dips, now may be as good a time as ever to start a position in what may be the leader in the insurance industry for years to come. 

In an environment where rapid quarter-after-quarter growth is the new expectation, and any sort of regression can cause a well-inflated stock to deflate in a hurry, investors are often provided with a nice buying opportunity off of these market overreactions.

In the third quarter revenue rose by 52% year-over-year from 2019, and the adjusted operating margin was an impressive 25%.

Palantir expects adjust profit in the range of $130 million to $136 million for the full year